Pathogen antigens and autoantibodies

Pathogen antigens and autoantibodies represent two distinct classes of immunological entities involved in infectious and autoimmune diseases. Pathogen antigens are molecules, such as the SARS-CoV-2 spike protein or bacterial lipopolysaccharides, that are recognized by the immune system as foreign, triggering a defensive response (NIH, 2023). Autoantibodies are immunoglobulins produced by the host that erroneously target self-antigens, contributing to the pathogenesis of diseases like systemic lupus erythematosus and myasthenia gravis (StatPearls, 2024). Therapeutic approaches differ significantly between these two groups: pathogen antigens are often targeted by vaccines or neutralizing monoclonal antibodies like Palivizumab to prevent or treat infections. Conversely, autoantibody-driven diseases are managed with B-cell depleting agents like Rituximab or FcRn inhibitors like Efgartigimod to reduce the burden of self-reactive proteins (FDA, 2021). Because this term aggregates broad categories of foreign and endogenous molecules rather than a specific protein or receptor, it is classified as a functional grouping rather than a single therapeutic target.

Other names

Microbial antigensSelf-reactive antibodiesAuto-antigen complexesInfectious agent antigens

Neutralization of microbial proteins to prevent infection, depletion of B-lymphocytes to reduce autoantibody production, or inhibition of the neonatal Fc receptor (FcRn) to accelerate the clearance of pathogenic IgG.